Opportunities for More Tailored Approaches to Genotoxicity Testing and Carcinogenicity Strategy for Oligonucleotide Therapeutics: Outcome of an Industry Survey
Joel D. Parry(Age UK), Yi Yan Yang(Institute of Bioengineering and Nanotechnology), Joanne Elloway(AstraZeneca (United Kingdom)), Melanie Guérard(Roche (Switzerland)), Tod A. Harper(Amgen (United States)), Meredith E. Crosby(Regeneron (United States)), Onyi N. Irrechukwu(Janssen (Belgium)), William E. Achanzar(Bristol-Myers Squibb (Germany)), Olivier Wattrelos(Laboratoire de Neurobiologie Cellulaire et Moléculaire), Nicole H.P. Cnubben(ProQR Therapeutics (Netherlands)), Natalie S. Holman(Eli Lilly (United States)), Patrik Andersson(Karolinska Institutet), Anthony Lynch(GlaxoSmithKline (United Kingdom)), Yann Tessier(Roche (Switzerland)), Marie Coeffet(Novo Nordisk (United States)), Eike Floettmann(Silence Therapeutics (United Kingdom))
Cited by 2
Related Papers
How to reduce false positive results when undertaking in vitro genotoxicity testing and thus avoid unnecessary follow-up animal tests: Report of an ECVAM Workshop
|Mutation Research/Genetic Toxicology and Environmental Mutagenesis|2007|437
A macromolecular approach to eradicate multidrug resistant bacterial infections while mitigating drug resistance onset
|Nature Communications|2018|330
Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation
|PLoS ONE|2010|127
Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis
|JCI Insight|2018|118